Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
News|Articles|March 31, 2026
Strategic Alliances in Bioprocessing and R&D: A Q&A with Dr. Manisha Desai of Bristol Myers Squibb
Author(s)Feliza Mirasol, Manisha P. Desai
Bristol Myers Squibb’s Dr. Manisha Desai, senior vice president of Product Development, notes how strategic bioprocessing alliances accelerate drug development by integrating R&D and manufacturing to scale complex biologics and ensure reliability.
Advertisement
Advertisement
Strategic partnerships have become a cornerstone of modern drug development, driving innovation across increasingly complex therapeutic landscapes. BioPharm International® discussed how these alliances are reshaping bioprocessing, biopharma R&D, and manufacturing workflows with
Related to this article
EA2251, the 7th registrational trial of ivonescimab, will test it plus chemotherapy vs pembrolizumab or durvalumab regimens in first-line BTC.
This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.
Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.
A patient with relapsing MS died of septic pneumonia 44 days after zola-cel CAR T infusion, as all 60 dose level 2 patients stayed off DMTs.
FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.
Advertisement
Advertisement